BUZZ-U.S. STOCKS ON THE MOVE-Cancer drugmakers, Altera, Om Group, Molycorp

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock index e-mini futures rose on Monday after closing down the previous week, as investors focused on the bright spots in China's factory activity data and ahead of a string of domestic economic data. Dow Jones industrial average futures were up 0.37 percent at 18,075, S&P 500 futures were up 0.27 percent at 2,111.75 and Nasdaq 100 futures were up 0.48 percent at 4,532.5.

** ALTERA CORP (NasdaqGS: ALTR - news) , Friday close $48.85, +6.08 pct premarket

** INTEL CORP, Friday close $34.46, -0.61 pct premarket

Intel (Swiss: INTC.SW - news) agreed to buy Altera for $16.7 billion as the world's biggest chipmaker seeks to make up for slowing demand from the PC industry by expanding its line-up of higher-margin chips used in data centers. The offer of $54 per share in cash is a 10.5 percent premium to Altera's Friday close.

** ONCOTHYREON INC (NasdaqGS: ONTY - news) , Friday close $3.42, +25.15 pct premarket

** VBL THERAPEUTICS, Friday close $8.05, +9.94 pct premarket

** EXELIXIS INC (NasdaqGS: EXEL - news) , Friday close $3.15, +11.75 pct premarket

** IMMUNOGEN INC (NasdaqGS: IMGN - news) , Friday close $8.98, +25.39 pct premarket

** IMMUNOMEDICS INC (NasdaqGM: IMMU - news) , Friday close $3.86, +6.22 pct premarket

The cancer drug makers presented data at the American Society of Clinical Oncology.

** CTI BIOPHARMA CORP (NasdaqCM: CTIC - news) , Friday close $1.94, +5.67 pct premarket

The drug developer said patients given its blood cancer drug showed improvement in key disease symptoms compared with those given a standard of care in a late-stage study.

** ATYR PHARMA INC (NasdaqGS: LIFE - news) , Friday close $22.89, +4.19 pct premarket

BMO started coverage of the drugmaker's stock with an "outperform" rating and a price target of $42, while JP Morgan started with an "overweight" rating and a $44 price target.

** ALPHA NATURAL RESOURCES INC (NYSE: ANR - news) , Friday close $0.4971, +14.67 pct premarket

** CLOUD PEAK ENERGY INC (NYSE: CLD - news) , Friday close $5.77, -5.20 pct premarket

** ARCH COAL INC (NYSE: ACI - news) , Friday close $0.49

Goldman Sachs (NYSE: GS-PB - news) upgraded Alpha Natural to "neutral" from "sell", saying concerns hurting the coal miner has already reflected on its stock. The brokerage assumed coverage of Arch Coal with "neutral" and cut its rating on Cloud Peak to "sell" from "neutral".

** MOLYCORP INC (NYSE: MCP - news) , Friday close $0.5301, -18.88 pct premarket

The rare earth miner is expected to announce on Monday that it would skip a $32.5 million loan payment, which might result in bankruptcy filing before the end of June, the Wall Street Journal reported.

** OM GROUP INC (NYSE: OMG - news) , Friday close $26.54, +27.88 pct premarket

Private equity firm Apollo Global Management LLC will buy the industrial magnet and battery maker for about $1.03 billion, or $34 per share - a premium of 28 percent to its Friday close.

** CELLDEX THERAPEUTICS INC (NasdaqGS: CLDX - news) , Friday close $28.87, -2.15 pct premarket

Adding an experimental Celldex Therapeutics vaccine that enlists the immune system to fight cancer to standard therapy helped patients with the deadliest type of brain cancer live longer, according to data from a mid-stage trial presented on Sunday.

** GENERAL ELECTRIC CO, Friday close $27.27, +0.00 pct premarket

The U.S. conglomerate has launched the sales process for a roughly $40 billion portion of its U.S. commercial lending assets as a part of its broad retreat from its finance businesses, sources familiar with the situation said on Sunday.

** COCA-COLA CO, Friday close $40.96

BMO raised the world's largest beverage maker's stock to "outperform" from "market perform" and price target to $48 from $44.

** PFIZER INC (NYSE: PFE - news) , Friday close $34.75

A Phase III trial of the drugmaker's Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer.

** PRANA BIOTECHNOLOGY LTD, Friday close $1.37, +18.25 pct premarket

The European Commission granted the Australian company's Huntington's disease treatment "orphan" drug status, which give the drug 10-year market exclusivity and funded research grants among other benefits.

** CELLADON CORP, Friday close $2.31, +16.01 pct premarket

The troubled drug developer said it was seeking an acquisition or a partnership after its heart drug failed in key mid-stage trial. The company also replaced its CEO with its CFO.

** MICROSOFT CORP, Friday close $46.86

The software company said on Monday its new Windows 10 operating system would be available worldwide on July 29 as a free upgrade for users of the most recent versions of Windows.

** JOHNSON & JOHNSON (NYSE: JNJ - news) , Friday close $100.14

An experimental biotech drug being developed by the company may offer hope to multiple myeloma patients who have run out of options, according to data from a mid-stage study released at a cancer meeting on Saturday (Shenzhen: 002291.SZ - news) .

** STIFEL FINANCIAL CORP (NYSE: SF - news) , Friday close $53.26, +0.98 pct premarket

The investment bank is in advanced talks to acquire Barclays (Swiss: BARC.SW - news) Plc's U.S wealth management unit, according to three people familiar with the situation.

** NVIDIA CORP, Friday close $22.13

The chipmaker said it expected cloud computing revenue to hit $1 billion in the next two to three years as demand for big data analysis drives growth in graphics chips.

** CYPRESS SEMICONDUCTOR CORP, Friday close $13.73

** INTEGRATED SILICON SOLUTION INC (NasdaqGS: ISSI - news) , Friday close $20.52

Cypress raised its offer to buy ISSI to $20.25 per share, beating Uphill Investment Co's increased offer. ISSI said it would hold talks with Cypress.

** WALT DISNEY CO, Friday close $110.37

The media company and theme park operator's shares could climb 50 percent over the next three years on its uncanny ability to generate profits from its businesses including movies, merchandise and parks and cruise lines, Barron's said in its latest edition published on Sunday.

** BRISTOL-MYERS SQUIBB, Friday close $64.6, +2.32 pct premarket

The company said the U.S. FDA accepted a marketing application for a combination of its cancer drugs Opdivo and Yervoy to treat melanoma as a first-line treatment. (Compiled by Abhirup Roy in Bengaluru; Editing by Kirti Pandey)